Last reviewed · How we verify

Dispersible NaCl powder 5 sessions

Suzana Erico Tanni Minamoto · Phase 2 active Small molecule

Dispersible NaCl powder 5 sessions is a Small molecule drug developed by Suzana Erico Tanni Minamoto. It is currently in Phase 2 development. Also known as: Breathox.

At a glance

Generic nameDispersible NaCl powder 5 sessions
Also known asBreathox
SponsorSuzana Erico Tanni Minamoto
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dispersible NaCl powder 5 sessions

What is Dispersible NaCl powder 5 sessions?

Dispersible NaCl powder 5 sessions is a Small molecule drug developed by Suzana Erico Tanni Minamoto.

Who makes Dispersible NaCl powder 5 sessions?

Dispersible NaCl powder 5 sessions is developed by Suzana Erico Tanni Minamoto (see full Suzana Erico Tanni Minamoto pipeline at /company/suzana-erico-tanni-minamoto).

Is Dispersible NaCl powder 5 sessions also known as anything else?

Dispersible NaCl powder 5 sessions is also known as Breathox.

What development phase is Dispersible NaCl powder 5 sessions in?

Dispersible NaCl powder 5 sessions is in Phase 2.

Related